Compare AbbVie Inc (ABBV) vs Royal Bank of Canada (RY) Price & Performance

AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).

Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.

Royal Bank of Canada (RY) trades at $209.07, up 2.09% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust fundamentals with a 31.85% net income margin and 17.17% ROE, supported by a $1.76 quarterly dividend and a share repurchase program. Revenue grew to $66.53B in 2025, and cash flow trends indicate improving operational strength.

RY presents a solid investment case with consistent profitability and shareholder returns, though valuation metrics like a P/E of 19.2 and P/B of 3.17 suggest premium pricing. Risks include economic sensitivity and high debt levels, but analyst consensus leans positive with 43% buy ratings. The outlook remains favorable if earnings growth persists amid macroeconomic stability.